-5%
Clonazepam, the active ingredient in Pase, is a benzodiazepine with anticonvulsant, sedative, muscle-relaxing, and anxiolytic properties. Its primary action involves enhancing GABAergic neurotransmission at inhibitory synapses. By binding to GABA receptors, clonazepam increases the affinity for GABA, enhancing chloride ion flux and inhibitory effects on neurons.
Additionally, clonazepam affects serotonin pathways and suppresses various paroxysmal EEG activities, including those seen in absence seizures, slow spike waves, and other focal or generalized epileptic discharges. These properties make it effective in treating both generalized and focal epilepsies.
Cilnidipine, a dihydropyridine calcium-channel blocker, acts by binding to L-type voltage-dependent calcium channels, reducing calcium ion (Ca²⁺) influx into vascular smooth muscle cells. This leads to muscle relaxation and vasodilation. Cilnidipine also inhibits Ca²⁺ influx via N-type calcium channels in sympathetic nerve membranes, reducing norepinephrine release and potentially preventing reflexive heart rate increases after blood pressure reduction.
